Anti-HIF-1 alpha antibody [RM1116],Abcam,AB317044

What are recombinant multiclonals? Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including: - The sensitivity of polyclonal antibodies by recognising multiple epitopes - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production View our range of recombinant multiclonal antibodies . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .

Host

Rabbit

Reactivity

Human, Mouse, Rat

Application

Flow Cyt (Intra), ICC/IF, WB

Platform ID

BAB892916925

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-HIF-1 alpha antibody [RM1116]
Cat. No.AB317044
HostRabbit
IsotypeIgG
ReactivityHuman, Mouse, Rat
ApplicationFlow Cyt (Intra), ICC/IF, WB
ClonalityMulticlonal
Clone NumberRM1116
Concentration0.506 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data The protein expressed by the gene HIF1A functions as a master transcriptional regulator of the adaptive response to hypoxia, activating the transcription of over 40 genes under hypoxic conditions, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and others. These genes' protein products enhance oxygen delivery or facilitate metabolic adaptation to hypoxia. HIF1A is crucial for embryonic vascularization, tumor angiogenesis, and ischemic disease pathophysiology. Its activation requires transcriptional coactivators like CREBBP and EP300, with activity enhanced by interactions with NCOA1 and/or NCOA2. Interaction with redox regulatory protein APEX1 activates CTAD and enhances activation by NCOA1 and CREBBP. Additionally, HIF1A is involved in axonal distribution and mitochondrial transport in neurons during hypoxia. In the context of microbial infection, specifically human coronavirus SARS-CoV-2, HIF1A is necessary for glycolysis induction in monocytes, leading to a proinflammatory state, inducing expression of ACE2, cytokines, and promoting virus replication and monocyte inflammatory response. This supplementary information is collated from multiple sources and compiled automatically. See full target information HIF1A

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.